Blinded SAPS-PD Assessment After 10 Weeks of Pimavanserin Treatment for Parkinson’s Disease Psychosis

Stuart H. Isaacsona,∗, Bruce Coateb, James Nortonb and Srdjan Stankovicb

a Parkinson’s Disease and Movement Disorders Center of Boca Raton, Boca Raton, FL, USA
bACADIA Pharmaceuticals Inc., San Diego, CA, USA

Accepted 19 June 2020

Abstract.
Background: Parkinson’s disease psychosis (PDP) is a common nonmotor symptom that affects up to 60% of patients. Pimavanserin, a selective 5-HT2A inverse agonist/antagonist, is approved for treating hallucinations and delusions associated with PDP.
Objective: Evaluate the efficacy and tolerability of pimavanserin in an open-label extension (OLE) study.
Methods: Patients completing a pivotal 6-week placebo-controlled trial (Core Study) could enroll in the OLE. All patients pimavanserin 34 mg once daily, blinded to previous treatment allocation. Prespecified blinded assessments at Week 4 were the Scale for the Assessment of Positive Symptoms (SAPS) PD version and SAPS H+D scales, Caregiver Burden Scale (CBS), and Clinical Global Impression (CGI) Improvement and Severity scales.
Results: Of 171 who entered the OLE, 148 (87%) completed Week 4. Among patients who received placebo in the Core Study, mean (SD) change from OLE baseline to OLE Week 4 for the SAPS-PD was –3.4 (6.3); p < 0.0001. Mean change from Core Study baseline to OLE Week 4 for SAPS-PD was similar among prior pimavanserin- and placebo-treated patients (–6.9 vs. –6.3). Improvement was similar with CGI-I, CGI-S, CBS, and SAPS-H+D in patients previously treated with placebo. Adverse events occurred in 92 (53.8%) patients during the 4-week OLE.
Conclusion: Improvements at OLE Week 4 from pretreatment baseline were similar with placebo and pimavanserin in the Core Study. The beneficial effects observed with pimavanserin in the 6-week Core Study were maintained for 4 weeks in the blinded OLE, supporting the durability of response with pimavanserin 34 mg for PDP over 10 weeks.

Keywords: Efficacy, Parkinson’s disease psychosis, pimavanserin, safety, tolerability

INTRODUCTION

Hallucinations and delusions are common neuropsychiatric symptoms in patients with Parkinson’s disease (PD), developing in over 50% of patients over the course of their disease with progression over time [1–3]. The onset of PD psychosis may be insidious and recognition may be delayed. PD psychosis complicates management of motor symptoms by limiting increases of dopaminergic medications, and its symptoms can result in anxiety, depression, stigma, social withdrawal, and increased caregiver burden [2]. Parkinson’s disease psychosis (PDP) is a major risk factor for hospitalization, prolonged hospitalization, nursing home placement, and mortality [4–8].
Treatment of PDP has relied on identifying provoking systemic illnesses, and minimizing anticholinergic and other offending medications. However, limiting dopaminergic therapy (i.e., not increasing when needed for motor symptoms for fear of worsening psychosis symptoms, or reducing medications with worsening motor symptoms) may have the consequence of increasing disability and morbidity. Prior to the approval of pimavanserin the only antipsychotics that did not worsen motor symptoms involved the off-label use of quetiapine or clozapine. All other antipsychotics typically worsen Parkinsonism through their blockade of postsynaptic D2 receptors, and MDS guidelines and Beers criteria caution against their use [9]. Recent guidelines from the MDS state that quetiapine has insufficient evidence with an acceptable risk and possibly clinically useful, and clozapine as efficacious but requiring specialized monitoring and clinically useful [10].

The selective 5-HT2A receptor inverse agonist, pimavanserin, is devoid of dopaminergic, histaminergic, adrenergic or muscarinic activity [11]. In a Phase 3, placebo-controlled study, pimavanserin 34 mg improved hallucinations and delusions associated with PDP, without worsening motor symptoms [12]. Perhaps related to the absence of other receptors affinities, daytime somnolence, orthostatic hypotension, and constipation were not identified as common adverse effects [12, 13]. Pimavanserin also improved daytime sleepiness and nocturnal sleep, and reduced caregiver burden over the 6-week treatment period [12]. Pimavanserin received regulatory approval by the FDA in the U.S. for the treatment of hallucinations and delusions associated with PDP in April 2016.

Patients who completed a double-blind, placebo-controlled, 6-week (Core) study were able to enroll in an open-label extension (OLE) trial to assess long-term durability and safety of pimavanserin treatment [14]. This paper reports the analysis of participants who completed the Core study and subsequently entered in the OLE. Clinical sites in North America enrolled patients in the OLE after completion of treatment with 34 mg pimavanserin or placebo for 6 weeks in the Core study (ACP-103-020, NCT01174004). During the initial 4 weeks of the OLE patients and site investigators remained blinded to the original treatment allocation in the Core study. Participants were evaluated at Week 4 using the primary endpoint of the blinded, placebo-controlled pivotal trial (i.e., SAPS-PD), as well as with SAPS-H + D, CBS, CGI-S and CGI-I. Additionally safety assessments were conducted at each study visit.

Baseline assessments were collected from patients and caregivers. For patients who were enrolled >1 week after completing the Core study, baseline assessments were completed at study entry. For patients who enrolled within 1 week of completing the Core study, baseline assessments were captured from those performed at the final Core study visit. A caregiver was required to accompany the patient to all visits, to provide information to study staff regarding the patient’s symptoms, and to complete a questionnaire to assess caregivers’ quality of life (Caregiver Burden Scale) [15]. Following baseline assessments, pimavanserin 34 mg was ingested orally by the patient once daily. Patients and site investigators remained blinded to the original treatment allocation from the Core study.

**Patient selection**

Patients who had completed the Core study within the past 28 days were eligible if the Investigator deter-
mined they could benefit from continued treatment with pimavanserin. Patients were required to be oriented to time, person, and place. All patients were required to provide informed consent or to have a caregiver who could provide informed consent on behalf of the patient. The caregiver had to agree to accompany the patient to all study visits. Women had to be of non-childbearing potential during the study or agree to use a clinically acceptable method of contraception during the study. Patients were required to have psychotic symptoms of at least moderate severity consistent with established diagnostic criteria for PDP [16]. Improvement of symptoms during the previous Core study was not required for entry into the OLE.

Patients were excluded for any clinically significant medical illness that might interfere with the conduct of the study; use of any prohibited or restricted medications; current use of medications known to prolong the QT interval; a baseline electrocardiogram (ECG) with Bazett’s corrected QT > 460 msec for males or >470 msec for females; or allergy or sensitivity to pimavanserin or other drugs of the same class.

**Study assessments**

Symptoms of psychosis were measured on Hallucination and Delusion subscales of the Scale for the Assessment of Positive Symptoms (SAPS) in North America by central, blinded, independent raters (MedAvante, Inc.) through remote video connection and outside North America by qualified off-site blinded raters. The SAPS-PD (modified 9-item SAPS hallucinations and delusions subscales) [17] and the SAPS-H + D (combined 20-item SAPS hallucinations and delusions subscales) [18] were evaluated at Week 4. The Clinical Global Impression-Severity and -Improvement (CGI-S and CGI-I) scales [19] and the Caregiver Burden Scale (CBS) [15] were scheduled after 2 weeks (±3 days) and 4 weeks (±3 days). Unscheduled study visits were allowed at any time. Patients who terminated the study at any time other than a planned study visit were required to have an end-of-study evaluation (early termination visit). At each study visit, physical and neurological examinations, vital signs (blood pressure and heart rate), standard clinical laboratory tests (chemistry, hematology, urinalysis), 12-lead ECG, and treatment-emergent adverse events (AEs) were assessed.

**RESULTS**

Patient data were collected between August 2010 and December 2012 from 66 clinical sites in North America. For the subgroup of patients that entered the OLE, this report summarizes the full 10 weeks of blinded treatment (6 weeks double blind plus the first 4 weeks of the open–label study). Of 176 patients who completed the ACP-103-020 study and were eligible to enroll, 171 entered the open-label extension (Fig. 1), and 154 (90.1%) patients remained in the study at the Week 4 time point (Table 1).

At OLE baseline, mean age was 72.6 years, 94.2% were white, and 60.8% were male; 88.8% of patients were at least 65 years and 32.7% were over 75 years of age (Table 2). Core study baseline mean SAPS-PD, SAPS-H + D, and CGI-S scores for patients previously on 34 mg pimavanserin were 15.9, 17.6, and 4.3, respectively and for those previously on placebo were 14.4, 15.4, and 4.3, respectively. Participants had a 120.7 month mean duration of PD with a mean 33.2 month duration of PDP. Demographic characteristics for patients entering the OLE were similar to the total population that entered the Core Study (Table 2).
Table 1
Baseline characteristics of study population at enrollment in the Core Study and OLE study

| Variable                  | Core Baseline (N = 171) | Placebo-PIM 34 (N = 84) | PIM 34-PIM 34 (N = 87) | PIM 34 (N = 171) |
|---------------------------|-------------------------|-------------------------|------------------------|------------------|
| Age, yearsa               | 72.6 (7.3)              | 72.6 (7.9)              | 72.6 (6.6)             | 72.6 (7.3)       |
| Age range                 | 53–90                   | 53–90                   | 56–85                  | 53–90            |
| Age category, n (%)       |                         |                         |                        |                  |
| <65 years                 | 19 (11.1)               | 9 (10.7)                | 10 (11.5)              | 19 (11.1)        |
| 65–75 years               | 96 (56.1)               | 48 (57.1)               | 48 (55.2)              | 96 (56.1)        |
| >75 years                 | 56 (32.7)               | 27 (32.1)               | 29 (33.3)              | 56 (32.7)        |
| Male, n (%)               | 104 (60.8)              | 48 (57.1)               | 56 (64.4)              | 104 (60.8)       |
| Female, n (%)             | 67 (39.2)               | 36 (42.9)               | 31 (35.6)              | 67 (39.2)        |
| Race, n (%)               |                         |                         |                        |                  |
| White                     | 161 (94.2)              | 79 (94.0)               | 82 (94.3)              | 161 (94.2)       |
| Black or African American | 2 (1.2)                 | 1 (1.2)                 | 1 (1.1)                | 2 (1.2)          |
| Asian                     | 0 (0.0)                 | 0 (0.0)                 | 0 (0.0)                | 0 (0.0)          |
| Other                     | 8 (4.7)                 | 4 (4.8)                 | 4 (4.6)                | 8 (4.7)          |
| Height, cm²               | 169.1 (11.1)            | 168.2 (11.7)            | 169.9 (10.7)           | 169.1 (11.2)     |
| Weight, kg²               | 75.4 (17.0)             | 73.9 (17.4)             | 76.8 (16.2)            | 75.4 (16.8)      |
| BMI, kg/m²a               | 26.2 (4.7)              | 26.1 (4.7)              | 26.4 (4.7)             | 26.2 (4.7)       |
| SAPS-PD a                 | 15.2 (5.8)              | 12.0 (7.3)              | 9.7 (7.1)              | 10.9 (7.3)       |
| SAPS-H + Da               | 16.5 (7.1)              | 12.8 (8.3)              | 10.6 (8.2)             | 11.7 (8.3)       |
| CGI-S²                    | 4.3 (0.9)               | 3.9 (1.3)               | 3.2 (1.3)              | 3.5 (1.3)        |

*a*mean (standard deviation).

Table 2
Adverse events occurring in the first 4 weeks of the OLE grouped by placebo controlled study treatment group (safety analysis set)

| Type of Event            | All Core Study (N = 171) | Placebo (N = 84) | PIM 34 mg (N = 87) | All (N = 171) |
|--------------------------|--------------------------|------------------|--------------------|---------------|
| ≥1 AE                    | 112 (65.5)               | 49 (58.3)        | 43 (49.4)          | 92 (53.8)     |
| ≥1 Drug-Related AE       | 30 (17.5)                | 20 (23.8)        | 12 (13.8)          | 32 (18.7)     |
| ≥1 SAE                   | 4 (2.3)                  | 2 (2.4)          | 0 (0.0)            | 2 (1.2)       |
| AE Leading to Study      | 0 (0.0)                  | 7 (8.3)          | 7 (8.0)            | 14 (8.2)      |

Durability of antipsychotic response

At OLE Week 4 (10 weeks total treatment duration), mean (SD) change from Core study baseline for the blinded SAPS-PD score was similar among prior pimavanserin and prior placebo-treated patients (−6.86 vs. −6.28) (Fig. 2A). Among patients entering the study having received placebo in the Core study, the mean (SD) change from OLE baseline to Week 4 blinded SAPS-PD score was −3.43 (6.3) \(p < 0.0001\). For patients previously dosed with pimavanserin 34 mg during the Core study, improvement from Core Study baseline was durable at Week 10 with a mean (SD) change from OLE baseline to Week 4 for the blinded SAPS–PD score of −0.43 (6.8). Mean (SD) SAPS–H + D scores decreased from OLE baseline to Week 4 in the overall population [−2.3 (7.5)], in those receiving prior placebo [−3.88 (7.0) \(p < 0.0001\)], and in those receiving prior pimavanserin 34 mg remained improved [−0.69 (7.6) \(p = 0.44\)] (Fig. 2B).

Participants with prior placebo in Core Study experienced improvement from OLE baseline in the mean SAPS–H score at Week 4 of −2.45 (4.8), \(p < 0.0001\); patients in the prior pimavanserin 34 mg group remained improved with a mean change of −0.18 (5.5). Patients with prior placebo had a mean change from baseline in the SAPS–D score at Week 4 of −1.43 (4.0) \(p = 0.0027\), and patients previously dosed with pimavanserin 34 mg had a mean change from OLE baseline of −0.51 (3.3) \(p = 0.18\). Overall, improvement in the SAPS–H and SAPS–D scores that was observed during the Core Study treatment persisted through Week 4 of open-label treatment, while scores improved among patients switched from placebo to pimavanserin.
Fig. 2. LS mean (SE) change from baseline for A) SAPS-PD score and B) SAPS H + D for patients who were in Study 020 and entered Study 015.

For all patients, the mean (standard error [SD]) CGI-S score at Core study baseline was 4.3 (0.9) and at OLE baseline was 3.9 (1.3) denoting mild symptoms. The mean change from OLE baseline to OLE Week 4 for the CGI-S regardless of previous treatment was –0.54 (1.1); the greatest improvement was in patients previously on placebo (–0.86 [1.1] p < 0.0001). Patients previously on pimavanserin had a modest improvement in the CGI-S (–0.24 [1.0] p = 0.04) indicating that the improvement over baseline seen in the Core Study was increased during the first 4 weeks of the OLE (Fig. 3A).

For CGI-I, the mean (SD) score at Week 2 and Week 4 of the OLE was 2.8 (1.3) and 2.6 (1.2), respectively. For patients previously on placebo, the mean (SD) CGI-I improvement from OLE baseline at Week 2 and Week 4 of the OLE was 2.9 (1.3) and 2.5 (1.2), respectively, while patients previously on pimavanserin remained stable CGI-I (SD) at Week 2 and Week 4 of the OLE with scores of 2.5 (1.1) and 2.6 (1.3), respectively. The proportion of CGI-I responders (very much improved or much improved) was 46.6% at Week 2 and 57.1% at Week 4 (Fig. 3B). The mean CBS score remained stable during the OLE. For patients previously on placebo the change from Core Baseline in CBS (SE) at Week 4 of the OLE was –1.62 (1.3), while patients previously on pimavanserin remained stable with the change from Core study baseline in CBS (SE) at Week 4 of the OLE of –2.6 (1.4) (Fig. 4).

Tolerability

Following 4 weeks (10 weeks total therapy) AEs causing discontinuation were reported by 6 (3.5%) patients (Table 2). The majority of AEs were of mild or moderate intensity, but 2 (1.2%) patients had serious AEs. The most common AEs were fall (7.0%), hallucination (3.5%), urinary tract infection (5.8%), and peripheral edema (2.9%) (Table 3). The incidence of drug-related AEs during OLE was 23.8% for previous placebo-treated patients and 13.8% for previous pimavanserin-treated patients. No clinically relevant changes were observed with pimavanserin for serum
Table 3
Treatment-emergent adverse events occurring ≥2% in all groups combined in the first 4 weeks of the OLE (safety analysis set)

| Type of Event          | All Core Study (N=171) | Placebo (N=84) | PIM 34 mg (N=87) | All (N=171) |
|------------------------|------------------------|----------------|------------------|-------------|
| Fall                   | 17 (9.9)               | 5 (6.0)        | 7 (8.0)          | 12 (7.0)    |
| Urinary tract infection| 17 (9.9)               | 7 (8.3)        | 3 (3.4)          | 10 (5.8)    |
| Insomnia               | 8 (4.7)                | 4 (4.8)        | 3 (3.4)          | 7 (4.1)     |
| Hallucination          | 3 (1.8)                | 4 (4.8)        | 2 (2.3)          | 6 (3.5)     |
| Oedema peripheral      | 9 (5.3)                | 3 (3.6)        | 2 (2.3)          | 5 (2.9)     |
| Excitiation            | 4 (2.3)                | 3 (3.6)        | 1 (1.1)          | 4 (2.3)     |
| Agitation              | 0 (0.0)                | 1 (1.2)        | 3 (3.4)          | 4 (2.3)     |
| Confusional state      | 4 (2.3)                | 0 (0.0)        | 4 (4.6)          | 4 (2.3)     |
| Psychotic disorder     | 1 (0.6)                | 2 (2.4)        | 2 (2.3)          | 4 (2.3)     |

chemistry, hematology or urinalysis or ECG findings including no clinically relevant changes in QTc interval.

DISCUSSION

During the OLE trial, participants completing the Core study underwent a prespecified, blinded, remote evaluation of the primary endpoint (SAPS-PD) used in the pivotal PDP trial after 4 weeks of open-label treatment. For participants who had received pimavanserin during the Core study, durability of improvement on SAPS-PD was demonstrated after 10 weeks total of pimavanserin treatment without additional safety concerns. Participants entering the OLE who had been randomized to the placebo arm in the Core study had similar improvement in the SAPS-PD after 4 weeks of open-label pimavanserin treatment, beginning after 2 weeks. Among those who switched from placebo to pimavanserin for the OLE, mean scores improved to the same level as the pimavanserin group over the next 4 weeks. This treatment effect was also seen for SAPS H + D, and improvement was maintained for CGI-I, CGI-S, and CGI-I response rates among patients who continued on pimavanserin. No new or unexpected adverse events were recorded.

In this OLE study, the mean change in SAPS-PD at OLE Week 4 was −3.4 points among patients on placebo in the Core study; this was comparable to the treatment effect observed for pimavanserin 34 mg over placebo in 6-week blinded studies of pimavanserin [12, 20]. The SAPS-PD scale retains the reliability, sensitivity to change, and effect size of the larger SAPS-H + D, with reduced score variability. Regression analyses using the SAPS-PD scale indicated that a clinically meaningful change in the CGI-I scale was associated with a 2.33-point change in the SAPS-PD score [17]. Thus, the results obtained in this OLE are consistent with a clinically meaningful improvement.

Prior to the availability of pimavanserin, clinical approaches for PDP treatment have relied on a reduction of dopaminergic medications, a strategy that can lead to worsening of motor symptoms and which also may not be effective in reducing PDP symptoms [9]. The off-label use of antipsychotics was needed. Since all prior antipsychotics are postsynaptic D2 receptor antagonists, all typical and atypical antipsychotics worsen motor symptoms in patients with PD except for quetiapine and clozapine. Indeed, MDS guidelines and Beers Criteria caution against the use of all except these two antipsychotics [21, 22]. However, clozapine is rarely used due to blood monitoring for agranulocytosis [9], and despite anecdotal experience the evidence supporting the efficacy and safety of quetiapine remains mixed with sedation and neuroleptic sensitivity common [23–28]. Anecdotal use of cholinesterase inhibitors and other medications have also been reported with varying success [29]. The availability of pimavanserin, an atypical antipsychotic targeting only serotonergic (i.e. 5–HT2A) receptors, without antagonism of dopaminergic and other receptors, is an important addition to the treatment paradigm for patients with PDP. Pimavanserin and clozapine are the only two antipsychotics that have demonstrated efficacy in relatively large, blinded, placebo-controlled trials without worsening motor symptoms [12, 30]. Durability of clinical improvement of PDP with pimavanserin after ten weeks of treatment provides additional information on this novel antipsychotic.

Limitations of this study were its open-label design and the lack of a comparison group. Another limitation is selection bias that could have resulted from the non-random selection of patients for the OLE. However, the blind was maintained amongst patients,
caregivers, investigators, and remote raters. These results provide the first efficacy and safety information beyond six weeks seen in the pivotal trial with pimavanserin in patients with PDP. These results reinforce that the treatment response observed during double-blind, randomized studies with pimavanserin is maintained during continued treatment for a total of 10 weeks.

Overall, the durability of response, and a sustained improvement in the severity of psychotic symptoms, as assessed with the SAPS-PD, Caregiver Burden, and CGI scales, was demonstrated in patients with PDP receiving treatment with pimavanserin 34 mg daily for 10 weeks.

ACKNOWLEDGMENTS

The authors acknowledge the editorial assistance of Richard S. Perry, PharmD in the preparation of this manuscript, which was supported by ACADIA Pharmaceuticals Inc., San Diego, CA. Tim Wright provided a quality control review of the manuscript.

Supported by ACADIA Pharmaceuticals Inc., San Diego, California.

CONFLICT OF INTEREST

SI: Honoraria for CME, consultant, research grants, and/or promotional speaker on behalf of: Abbvie, Acadia, Acorda, Adamas, Addex, Allergan, Amaranus, Axovant, Biogen, Britannia, Eli Lilly, Enterin, GE Healthcare, Global Kinetics, Impax, Intec Pharma, Kyowa, Lundbeck, Michael J. Fox Foundation, Neurocrine, Neuroderm, Parkinson Study Group, Pharma2B, Roche, Sanofi, Sunovion, Teva, UCB, US World Meds, Zambon.

BC, IN, and SS were employees of ACADIA Pharmaceuticals, Inc. and may have owned stock in the company.

REFERENCES

[1] Fenelon G, Alves G (2010) Epidemiology of psychosis in Parkinson’s disease. J Neurol Sci 289, 12-17.
[2] Forsaa EB, Larsen JP, Wentzel-Larsen T, Goetz CG, Stebbins GT, Aarsland D, Alves G (2010) A 12-year population-based study of psychosis in Parkinson disease. Arch Neurol 67, 996-1001.
[3] Goetz CG, Fan W, Leurgans S, Bernard B, Stebbins GT (2006) The malignant course of “benign hallucinations” in Parkinson disease. Arch Neurol 63, 713-716.
[4] Aarsland D, Larsen JP, Tandberg E, Laake K (2000) Predictors of nursing home placement in Parkinson’s disease: A population-based, prospective study. J Am Geriatr Soc 48, 938-942.
[5] Friedman JH (2010) Parkinson’s disease psychosis 2010: A review article. Parkinsonism Relat Disord 16, 553-560.
[6] Factor SA, Feustel PJ, Friedman JH, Comella CL, Goetz CG, Kurlan R, Parsa M, Pfeiffer R; Parkinson Study Group (2003) Longitudinal outcome of Parkinson’s disease patients with psychosis. Neurology 60, 1756-1761.
[7] Goetz CG, Stebbins GT (1993) Risk factors for nursing home placement in advanced Parkinson’s disease. Neurology 43, 2227-2229.
[8] Goetz CG, Stebbins GT (1995) Mortality and hallucinations in nursing home patients with advanced Parkinson’s disease. Neurology 45, 669-671.
[9] Goldman JG, Vaughan CL, Goetz CG (2011) An update expert opinion on management and research strategies in Parkinson’s disease psychosis. Expert Opin Pharmacother 12, 2009-2024.
[10] Seppi K, Ray Chaudhuri K, Coelho M, Fox SH, Katzenschlager R, Perez Llorot S, Weintraub D, Sampaio C; the collaborators of the Parkinson’s Disease Update on Non-Motor Symptoms Study Group on behalf of the Movement Disorders Society Evidence-Based Medicine Committee (2019) Update on treatments for nonmotor symptoms of Parkinson’s disease—an evidence-based medicine review. Mov Disord 34, 180-198.
[11] Hacksell U, Burstein ES, McFarland K, Mills RG, Williams H (2014) On the discovery and development of pimavanserin: A novel drug candidate for Parkinson’s psychosis. Neurochem Res 39, 2008-2017.
[12] Cummings J, Isaacson S, Mills R, Williams H, Chi-Burris K, Corbett A, Dhall R, Ballard C (2014) Pimavanserin for patients with Parkinson’s disease psychosis: A randomised, placebo-controlled phase 3 trial. Lancet 383, 533-540.
[13] Correll CU (2010) From receptor pharmacology to improved outcomes: Individualising the selection, dosing, and switching of antipsychotics. Eur Psychiatry 25 Suppl 2, S12-21.
[14] Mills R, Williams H, Chi-Burris K, Ballard C (2013) Long-term pimavanserin treatment for Parkinson’s Disease Psychosis (PDP): An interim analysis of safety and tolerability data from study ACP-103-015. Paper presented at: 17th International Congress on Parkinson’s Disease; Sydney, Australia.
[15] Zarit SH, Reever KE, Bach-Peterson J (1980) Relatives of the impaired elderly: Correlates of feelings of burden. Gerontologist 20, 649-655.
[16] Ravina B, Marder K, Fernandez HH, Friedman JH, MacDonald W, Murphy D, Aarsland D, Babcock D, Cummings J, Endicott J, Factor S, Galpern W, Lees A, Marsh L, Stacy M, Gwinn-Hardy K, Voon V, Goetz C (2007) Diagnostic criteria for psychosis in Parkinson’s disease: Report of an NINDS, NIMH work group. Mov Disord 22, 1061-1068.
[17] Voss T, Bahr D, Cummings J, Mills R, Ravina B, Williams H (2013) Performance of a shortened Scale for Assessment of Positive Symptoms for Parkinson’s disease psychosis. Parkinsonism Relat Disord 19, 295-299.
[18] Andreasen NC (1984) Scale for the assessment of positive symptoms (SAPS). University of Iowa, College of Medicine, Iowa City, Iowa.
[19] Guy WG (1976) ECDEU Assessment Manual for Psychopharmacology. ECDEU, Rockville, MD.
[20] Friedman JH, Ravina B, Mills R (2010) A multi-center, placebo-controlled, double-blind trial to examine the safety and efficacy of pimavanserin in the treatment of Parkinson’s...
Disease psychosis (ACP-103-012). *Mov Disord* **25**(Suppl 2), S292.

[21] American Geriatrics Society Beers Criteria Update Expert Panel (2015) American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. *J Am Geriatr Soc* **63**, 2227-2246.

[22] Seppi K, Weintraub D, Coelho M, Perez-Lloret S, Fox SH, Katzschlager R, Hametner EM, Poewe W, Rascol O, Goetz CG, Sampaio C (2011) The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson’s disease. *Mov Disord* **26** Suppl 3, S42-80.

[23] Fernandez HH, Okun MS, Rodriguez RL, Malaty IA, Romrell J, Sun A, Wu SS, Pillarisetty S, Nyathappa A, Eisenschink S (2009) Quetiapine improves visual hallucinations in Parkinson disease but not through normalization of sleep architecture: Results from a double-blind clinical-polysomnography study. *Int J Neurosci* **119**, 2196-2205.

[24] Morgante L, Epifanio A, Spina E, Zappia M, Di Rosa AE, Marconi R, Basile G, Di Raimondo G, La Spina P, Quattrone A (2004) Quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis. *Clin Neuropharmacol* **27**, 153-156.

[25] Ondo WG, Tintner R, Youngh D, Lai D, Ringholz G (2005) Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson’s disease. *Mov Disord* **20**, 958-963.

[26] Rabey JM, Prokhorov T, Miniovitz A, Dobronevsky E, Klein C (2007) Effect of quetiapine in psychotic Parkinson’s disease patients: A double-blind labeled study of 3 months’ duration. *Mov Disord* **22**, 313-318.

[27] Shotbolt P, Samuel M, David A (2010) Quetiapine in the treatment of psychosis in Parkinson’s disease. *Ther Adv Neurol Disord* **3**, 339-350.

[28] Merims D, Balas M, Peretz C, Shabtai H, Giladi N (2006) Rater-blinded, prospective comparison: Quetiapine versus clozapine for Parkinson’s disease psychosis. *Clin Neuropharmacol* **29**, 331-337.

[29] Goldman JG, Holden S (2014) Treatment of psychosis and dementia in Parkinson’s disease. *Curr Treat Options Neurol* **16**, 281.

[30] The French Clozapine Parkinson Study Group (1999) Clozapine in drug-induced psychosis in Parkinson’s disease. *Lancet* **353**, 2041-2042.